Inventor
STAELENS STEPHANIE
BE23 patents
⚠️ This page may combine multiple inventors who share the name “STAELENS STEPHANIE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABLYNX NV
14 patentsUS10858418B2Dec 8, 2020
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV18 citations93
US9803001B2Oct 31, 2017
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
ABLYNX NV4 citations84
US11192937B2Dec 7, 2021
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV5 citations83
US11192938B2Dec 7, 2021
Serum albumin binding proteins containing immunoglobulin single variable domains
ABLYNX NV5 citations83
US11414481B2Aug 16, 2022
Serum albumin binders
ABLYNX NV6 citations82
US11414480B2Aug 16, 2022
Serum albumin binding immunoglobulin single variable domains
ABLYNX NV6 citations78
US12516105B2Jan 6, 2026
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations74
US12006352B2Jun 11, 2024
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV1 citations72
US11644471B2May 9, 2023
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ABLYNX NV2 citations72
US9834611B2Dec 5, 2017
Single variable domain antibodies against OX40L, constructs and therapeutic use
ABLYNX NV2 citations70
US11028151B2Jun 8, 2021
Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
ABLYNX NV0 citations62
US11466089B2Oct 11, 2022
Chemokine receptor binding polypeptides
ABLYNX NV0 citations61
US11897944B2Feb 13, 2024
Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
ABLYNX NV1 citations59
US10822425B2Nov 3, 2020
Single variable domain antibodies against OX40L, constructs and therapeutic use
ABLYNX NV0 citations49
BOEHRINGER INGELHEIM INT
4 patentsUS11952418B2Apr 9, 2024
Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
BOEHRINGER INGELHEIM INT2 citations71
US11033636B2Jun 15, 2021
Polypeptides antagonizing Wnt signaling in tumor cells
BOEHRINGER INGELHEIM INT2 citations71
US10597449B2Mar 24, 2020
Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
BOEHRINGER INGELHEIM INT4 citations71
US12285493B2Apr 29, 2025
Polypeptides antagonizing Wnt signaling in tumor cells
BOEHRINGER INGELHEIM INT0 citations60